Global Uranium and Enrichment Limited (ASX: GUE) announced that Urenco has received Foreign Investment Review Board approval to move ahead with its investment in Ubaryon, where GUE holds a 21% cornerstone interest. The approval allows both parties to progress their strategic partnership, centred on Ubaryon’s chemical-based uranium enrichment technology, which avoids the traditional UF6 conversion and deconversion steps. This streamlined approach has the potential to simplify the fuel-cycle workflow and offer greater operational flexibility.
Urenco’s long-standing experience across global enrichment markets brings vital commercial, technical and regulatory strength to the next phase of Ubaryon’s development. Ubaryon continues to operate under strict oversight to ensure compliance with security and non-proliferation standards. With the approval secured, the partners will advance toward commercial evaluation and scaling opportunities, positioning GUE to benefit from emerging advancements in the enrichment-technology space.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au.au.au
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Urenco Investment Approval Accelerates Ubaryon’s Enrichment Technology Pathway
Global Uranium and Enrichment Limited (ASX: GUE) announced that Urenco has received Foreign Investment Review Board approval to move ahead with its investment in Ubaryon, where GUE holds a 21% cornerstone interest. The approval allows both parties to progress their strategic partnership, centred on Ubaryon’s chemical-based uranium enrichment technology, which avoids the traditional UF6 conversion and deconversion steps. This streamlined approach has the potential to simplify the fuel-cycle workflow and offer greater operational flexibility.
Urenco’s long-standing experience across global enrichment markets brings vital commercial, technical and regulatory strength to the next phase of Ubaryon’s development. Ubaryon continues to operate under strict oversight to ensure compliance with security and non-proliferation standards. With the approval secured, the partners will advance toward commercial evaluation and scaling opportunities, positioning GUE to benefit from emerging advancements in the enrichment-technology space.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au.au.au